Aliases & Classifications for Degenerative Disc Disease

MalaCards integrated aliases for Degenerative Disc Disease:

Name: Degenerative Disc Disease 12 54 15 37
Cervical Disc Degenerative Disorder 17 70
Intervertebral Disc Degeneration 12 70
Degeneration of Lumbar Intervertebral Disc 70
Cervical Disc Degenerative Disease 12
Intervertebral Disc Disorder 70
Lumbar Disc Degeneration 12
Vertebral Disc Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:90
NCIt 50 C27156
SNOMED-CT 67 156633005
ICD10 32 M51.3
UMLS 70 C0158252 C0158266 C0263874 more

Summaries for Degenerative Disc Disease

Disease Ontology : 12 A bone deterioration disease that has material basis in gradual dehydration and tears located in intervertebral disc.

MalaCards based summary : Degenerative Disc Disease, also known as cervical disc degenerative disorder, is related to intervertebral disc disease and back pain, and has symptoms including sciatica An important gene associated with Degenerative Disc Disease is LINC01562 (Long Intergenic Non-Protein Coding RNA 1562), and among its related pathways/superpathways are Degradation of the extracellular matrix and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Oxycodone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include Cartilage.

Wikipedia : 73 Degenerative disc disease (DDD) is a medical condition in which there are anatomic changes and a loss of... more...

Related Diseases for Degenerative Disc Disease

Diseases related to Degenerative Disc Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 intervertebral disc disease 32.3 VDR COL9A3 ASPN
2 back pain 31.7 COL9A3 ASPN
3 spinal stenosis 31.1 COL9A3 CALCA ACAN
4 spondylosis 31.0 VDR BMP2 ACAN
5 spondylolisthesis 30.9 GDF5 COL9A3 BMP2 ACAN
6 osteoarthritis 30.6 SOX9 GDF5 ASPN ACAN
7 osteochondrosis 30.4 VDR COL9A3 ACAN
8 discitis 30.4 CALCA ACAN
9 ankylosis 30.3 HIF1A GDF5 BMP2
10 bone resorption disease 30.3 VDR CALCA BMP2
11 pain agnosia 30.3 TRPV1 COMT CALCA
12 paine syndrome 30.3 TRPV1 COMT CALCA
13 spondylolysis 30.3 GDF5 BMP2 ACAN
14 exostosis 30.1 GDF5 CALCA BMP2 ACAN
15 bone disease 30.0 VDR GDF5 CALCA BMP2 ACAN
16 disease of mental health 28.9 TRPV1 SOX9 MIR155 MIR132 HIF1A COMT
17 spondyloepiphyseal dysplasia with congenital joint dislocations 11.2
18 loeys-dietz syndrome 3 11.2
19 radiculopathy 10.7
20 aging 10.5
21 acute tympanitis 10.4 GDF5 ASPN
22 spondylosis, cervical 10.4
23 scoliosis 10.4
24 scoliosis, isolated 1 10.3
25 idiopathic scoliosis 10.3
26 hypervitaminosis d 10.3 VDR CALCA
27 rapidly involuting congenital hemangioma 10.3
28 dysphagia 10.3
29 hypochondrogenesis 10.3 ASPN ACAN
30 epicondylitis 10.3 CALCA ACAN
31 myofascial pain syndrome 10.3 TRPV1 CALCA
32 causalgia 10.3 TRPV1 CALCA
33 detrusor sphincter dyssynergia 10.3 TRPV1 CALCA
34 somatoform disorder 10.3 TRPV1 COMT CALCA
35 retinitis pigmentosa 11 10.3
36 iron metabolism disease 10.3
37 hyperglycemia 10.3
38 congenital extrahepatic portosystemic shunt 10.3
39 agnosia 10.3 TRPV1 COMT CALCA
40 hypercalcemia, infantile, 1 10.3 VDR CALCA
41 ulnar nerve lesion 10.2 VDR COMT BMP2
42 diabetes mellitus 10.2
43 glucocorticoid-induced osteoporosis 10.2 VDR CALCA BMP2
44 ischemic bone disease 10.2 CALCA BMP2 ACAN
45 reflex sympathetic dystrophy 10.2 TRPV1 CALCA
46 brachydactyly, type a1, b 10.2 GDF5 BMP2
47 cleidocranial dysplasia 10.2 SOX9 BMP2 ACAN
48 retinoblastoma 10.2
49 triiodothyronine receptor auxiliary protein 10.2
50 allergic disease 10.2

Graphical network of the top 20 diseases related to Degenerative Disc Disease:



Diseases related to Degenerative Disc Disease

Symptoms & Phenotypes for Degenerative Disc Disease

UMLS symptoms related to Degenerative Disc Disease:


sciatica

Drugs & Therapeutics for Degenerative Disc Disease

Drugs for Degenerative Disc Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Eplerenone Approved Phase 4 107724-20-9 150310 443872
6
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
7 Analgesics Phase 4
8 Narcotics Phase 4
9 Analgesics, Opioid Phase 4
10 Psychotropic Drugs Phase 4
11 Dopamine Agents Phase 4
12 Antidepressive Agents Phase 4
13 Duloxetine Hydrochloride Phase 4
14 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
15 Mineralocorticoids Phase 4
16 Mineralocorticoid Receptor Antagonists Phase 4
17 diuretics Phase 4
18 Pharmaceutical Solutions Phase 4
19 Anesthetics Phase 4
20 Anesthetics, Local Phase 4
21
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
22
tannic acid Approved Phase 3 1401-55-4
23
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
24
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
25
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
26
Racepinephrine Approved Phase 3 329-65-7 838
27
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
28
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
29 Calcium, Dietary Phase 3
30 Anti-Arrhythmia Agents Phase 3
31 Diuretics, Potassium Sparing Phase 2, Phase 3
32 Mitogens Phase 2, Phase 3
33 Respiratory System Agents Phase 3
34 Neurotransmitter Agents Phase 3
35 Sodium Channel Blockers Phase 2, Phase 3
36 Adrenergic alpha-Agonists Phase 3
37 Adrenergic Agonists Phase 3
38 Adrenergic Agents Phase 3
39 Anti-Asthmatic Agents Phase 3
40 Adrenergic beta-Agonists Phase 3
41 Epinephryl borate Phase 3
42 Vasoconstrictor Agents Phase 3
43 Mydriatics Phase 3
44 Sympathomimetics Phase 3
45 Bronchodilator Agents Phase 3
46 Viscosupplements Phase 3
47 Adjuvants, Immunologic Phase 3
48 Fibrin Tissue Adhesive Phase 3
49 Coagulants Phase 3
50 Hemostatics Phase 3

Interventional clinical trials:

(show top 50) (show all 359)
# Name Status NCT ID Phase Drugs
1 Clinical Investigation of NanoFUSE® Bioactive Matrix and Autogenous Bone in Posterolateral Spinal Fusion (Nonloadbearing) Unknown status NCT03751943 Phase 4
2 A Prospective, Multi-Center, Post-Market Surveillance Study to Assess the Clinical Efficacy and Fusion Rates of the Zimmer TM Ardis Interbody Fusion System Completed NCT02429908 Phase 4
3 Comparison of Internal Disc Decompression (IDD) vs. a Standardized Non-surgical Treatment Program for Chronic Low Back Pain Secondary to Mild to Moderate Degenerative Disc Disease (DDD) Completed NCT00165893 Phase 4
4 Clinical and Radiographic Outcomes of BIO4 Bone Matrix in Patients Undergoing 1 or 2-Level Anterior Cervical Discectomy and Fusion Surgery Completed NCT03077204 Phase 4
5 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Completed NCT02535000 Phase 4 Duloxetine;Placebo
6 Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain Completed NCT00443781 Phase 4
7 Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™ Completed NCT01615328 Phase 4
8 Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms Completed NCT01502644 Phase 4 Oxycodone;Morphine;Placebo
9 Orthokine Therapy in Lumbar Degenerative Disease: Does the Route of Administration Really Matter Recruiting NCT04734327 Phase 4
10 Comparison of Rigid and Non-Rigid Interbody Fusion Device for Cervical Degenerative Disc Disease in Adults - A Randomized, Prospective, Multicenter Clinical Trial Recruiting NCT04550923 Phase 4
11 A Prospective, Single Arm Study of Patients Undergoing Posterolateral Lumbar Fusion (Without Interbody) Supplemented With ViviGen Cellular Bone Matrix Recruiting NCT04007094 Phase 4 ViviGen Cellular Bone Matrix
12 Epidural Steroid Injection With Supplemental Oral Eplerenone for Low Back Pain: A Prospective, Double Blind Randomized Trial Suspended NCT03418649 Phase 4 Eplerenone 50 Mg Tab;Placebo Oral Tablet
13 A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease Terminated NCT00700739 Phase 4
14 Combined Administration of Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Analgesia in Posterior Lumbar Spine Surgery - A Prospective Randomized Study Terminated NCT03514277 Phase 4 Exparel;Bupivacaine
15 Efficacy Study Using Solum IV, Bone Marrow Concentrate With General Fluid Concentrate in Transforaminal Lumbar Interbody Fusion Withdrawn NCT03223701 Phase 4
16 A Prospective, Multi-center, Randomized, Active-Controlled Study of the Wallis System for the Treatment of Mild to Moderate Degenerative Disc Disease of the Lumbar Spine Unknown status NCT00484458 Phase 3
17 A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease Completed NCT00707265 Phase 3
18 A Pivotal, Multi-Center, Clinical Trial Evaluating The Safety And Effectiveness of The Lumbar TDR Device In Patients With Single-Level Lumbar Degenerative Disc Disease Completed NCT00927238 Phase 3
19 A Prospective, Multicenter, Controlled Clinical Trial of an Artificial Cervical Disc LP at a Single Level for Symptomatic Cervical Disc Disease Completed NCT00667459 Phase 3
20 A Multi-center Study to Evaluate the Safety and Efficacy of DePuy AcroMed Titanium Surgical Mesh and MOSS-Miami Spinal Fixation System Pedicle Screws for Intradiscal Fusion in the Lumbar Spine Completed NCT00215319 Phase 3
21 A Prospective, Multicenter, Randomized Study Comparing the Use of HEALOS® to Autograft in a Transforaminal Lumbar Interbody Fusion (TLIF) Approach Completed NCT00316121 Phase 3
22 Clinical Investigation of the SB Charite III Intervertebral Disc Spacer. Completed NCT00215306 Phase 3
23 A Randomized Multi-Center Study to Evaluate the Safety and Efficacy of the Cervical I/F Cage for Anterior Cervical Fusion Completed NCT00215293 Phase 3
24 Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies. Completed NCT01694134 Phase 3 Hydrocortancyl.;Lidocaine
25 "A Prospective, Randomized Controlled Clinical Investigation of MAVERICK™ Total Disc Replacement in Patients With Degenerative Disc Disease" Completed NCT00635843 Phase 3
26 A Phase 2/3 Prospective, Multicentre Randomized, Double-blind Trial, Comparing Intra-discal Allogeneic Adult BM-MSC Therapy and Sham-treated Controls in Subjects With Chronic LBP Due to Lumbar DDD Unresponsive to Conventional Therapy Recruiting NCT03737461 Phase 2, Phase 3 Allogenic BM-MSCs Injection
27 Efficacy of Peri-Incisional Multimodal Drug Injection in Reducing Post-Operative Pain Following Lumbar Spine Surgery Recruiting NCT03513445 Phase 3 Morphine;Epinephrine;naropin
28 Evaluation of Regenerative Medicine Treatment Outcomes With Amniotic Fluid for Musculoskeletal Conditions Recruiting NCT03390920 Phase 2, Phase 3
29 A Prospective Registry Study Evaluating the Safety and Efficacy of Fibrin for Chronic Multi-level Discogenic Low Back Pain Recruiting NCT04621799 Phase 2, Phase 3 Fibrin sealant
30 A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain Active, not recruiting NCT02412735 Phase 3 rexlemestrocel-L;rexlemestrocel-L + HA;Placebo
31 Study of Bone of Marrow Concentrate (BMC) Injection in Discs, Facets, Sacroiliac Joints, and Epidural Space for Chronic Lower Back Pain With and Without Radiculopathy Active, not recruiting NCT04559295 Phase 2, Phase 3
32 Intradiscal and Intra-articular Injection of Autologous Platelet-Rich-Plasma (PRP) in Patients With Lumbar Degenerative Disc Disease and Facet Joint Syndrome: A Prospective, Single-arm, Open Label Clinical Trial Not yet recruiting NCT04816747 Phase 3
33 A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System Terminated NCT01011816 Phase 3 Saline
34 Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion Withdrawn NCT03327272 Phase 3 Methylprednisolone;Saline
35 A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion Unknown status NCT00798902 Phase 1, Phase 2
36 A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion Unknown status NCT00798239 Phase 1, Phase 2
37 Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease Unknown status NCT01799616 Phase 2 Pamidronate
38 Phase I/II, Multicenter, Open-label, Single Administration, Dose Finding, Clinical Trial to Evaluate the Safety and Tolerability of Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration Completed NCT00813813 Phase 1, Phase 2 Intradiscal rhGDF-5
39 A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration Completed NCT01124006 Phase 2 Intradiscal rhGDF-5
40 A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration Completed NCT01182337 Phase 1, Phase 2 Intradiscal rhGDF-5;Vehicle control
41 A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration Completed NCT01158924 Phase 1, Phase 2 Intradiscal rhGDF-5
42 A Double-blind, Randomized, Parallel, Placebo Controlled, Phase I/II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH14618 Following Single Intradiscal Injection in Patients With Degenerative Disc Disease Completed NCT01526330 Phase 1, Phase 2 YH14618;YH14618;YH14618;Placebo
43 Clinical Trial Phase I / II Prospective, Open, Non-randomized for Treatment of Lumbar Intervertebral Degenerative Disc Disease With Posterolateral Instrumented and Autologous Mesenchymal Stem Cells. Completed NCT01513694 Phase 1, Phase 2
44 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Trial to Evaluate the Efficacy and Safety of YH14618 in Patients With Lumbar Degenerative Disc Disease Completed NCT02320019 Phase 2 Placebo;YH14618
45 Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure Completed NCT01860417 Phase 1, Phase 2 Mepivacaine
46 A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain Completed NCT01290367 Phase 2
47 A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation. Completed NCT00549913 Phase 1, Phase 2
48 A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation Completed NCT00996073 Phase 2
49 Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation Completed NCT01106417 Phase 1, Phase 2
50 Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation Completed NCT01097486 Phase 2

Search NIH Clinical Center for Degenerative Disc Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Degenerative Disc Disease cell therapies at LifeMap Discovery.

Genetic Tests for Degenerative Disc Disease

Anatomical Context for Degenerative Disc Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Degenerative Disc Disease:

19
Intervertebral Disc

MalaCards organs/tissues related to Degenerative Disc Disease:

40
Bone, Bone Marrow, Spinal Cord, Endothelial, Placenta, Dorsal Root Ganglion, Pineal
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Degenerative Disc Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Annulus Fibrosus Intervertebral Disc Annulus Fibrosus Cells Affected by disease
2 Cartilage Nucleus Pulposus Intervertebral Disc Nucleus Pulposus Cells Affected by disease
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Degenerative Disc Disease

Articles related to Degenerative Disc Disease:

(show top 50) (show all 3933)
# Title Authors PMID Year
1
The genetics of intervertebral disc degeneration. Associated genes. 61 54
18485784 2008
2
Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. 54 61
17669279 2007
3
Differentially-expressed mRNAs, microRNAs and long noncoding RNAs in intervertebral disc degeneration identified by RNA-sequencing. 61
33764282 2021
4
Autophagy as a potential therapeutic target in intervertebral disc degeneration. 61
33631177 2021
5
Effects of Axial Compression and Distraction on Vascular Bud and VEGFA Expression in the Vertebral Endplate of an Ex Vivo Rabbit Spinal Motion Segment Culture Model. 61
33186278 2021
6
Reciprocal relationship between multifidus and psoas at L4-L5 level in women with low back pain. 61
32576034 2021
7
Substance P Mediates Estrogen Modulation Proinflammatory Cytokines Release in Intervertebral Disc. 61
32965648 2021
8
A20 regulates inflammation through autophagy mediated by NF-κB pathway in human nucleus pulposus cells and ameliorates disc degeneration in vivo. 61
33677390 2021
9
Involvement of oxidative stress-induced annulus fibrosus cell and nucleus pulposus cell ferroptosis in intervertebral disc degeneration pathogenesis. 61
32892384 2021
10
Development of a Multivariate Prediction Model for Successful Oswestry Disability Index Changes in L5/S1 Anterior Lumbar Interbody Fusion for Degenerative Disc Disease. 61
33189919 2021
11
The anterior and traverse cage can provide optimal biomechanical performance for both traditional and percutaneous endoscopic transforaminal lumbar interbody fusion. 61
33676337 2021
12
Coagulation Profile as a Significant Risk Factor for Short-Term Complications and Mortality after Anterior Cervical Discectomy and Fusion. 61
33307267 2021
13
Cartilage endplate stem cells inhibit intervertebral disc degeneration by releasing exosomes to nucleus pulposus cells to activate Akt/autophagy. 61
33459443 2021
14
The potential role and trend of HIF‑1α in intervertebral disc degeneration: Friend or foe? (Review). 61
33537810 2021
15
Granulocyte-colony stimulating factor improves intervertebral disc degeneration in experimental adult male rats: A microscopic and radiological study. 61
33015986 2021
16
Elevated BMI is considerably associated with IDD rather than polymorphic variations in interleukin-1 and vitamin D receptor genes: A case-control study. 61
33776562 2021
17
Cardamonin protects nucleus pulposus cells against IL-1β-induced inflammation and catabolism via Nrf2/NF-κB axis. 61
33666626 2021
18
The miR-623/CXCL12 axis inhibits LPS-induced nucleus pulposus cell apoptosis and senescence. 61
33333129 2021
19
Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study. 61
33706752 2021
20
Elucidating the role of cell-mediated inflammatory cytokines on allogeneic mouse-derived nucleus pulposus mesenchymal stem cells. 61
33694170 2021
21
Co-culture with Sirt1-overexpressed chondrocytes delays the nucleus pulposus cells degeneration. 61
33683504 2021
22
Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway. 61
33713325 2021
23
Inhibition of HDAC4 by GSK3β leads to downregulation of KLF5 and ASK1 and prevents the progression of intravertebral disc degeneration. 61
33691773 2021
24
The Application of Mesenchymal Stromal Cells and Their Homing Capabilities to Regenerate the Intervertebral Disc. 61
33805356 2021
25
The effects of axial loading on the morphometric and T2 characteristics of lumbar discs in relation to disc degeneration. 61
33596534 2021
26
Comprehensive RNA expression profile of therapeutic adipose‑derived mesenchymal stem cells co‑cultured with degenerative nucleus pulposus cells. 61
33398382 2021
27
Hypoxia and Hypoxia-Inducible Factor-1α Regulate Endoplasmic Reticulum Stress in Nucleus Pulposus Cells: Implications of Endoplasmic Reticulum Stress for Extracellular Matrix Secretion. 61
33307037 2021
28
Biologic Therapy in Chronic Pain Management: a Review of the Clinical Data and Future Investigations. 61
33761016 2021
29
Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. 61
33774593 2021
30
Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model. 61
33740525 2021
31
ACTG1 regulates intervertebral disc degeneration via the NF-κB-p65 and Akt pathways. 61
33545632 2021
32
Number of Levels of Spinal Fusion Associated with the Rate of Joint-Space Narrowing in the Hip. 61
33770019 2021
33
The mechanism of Bushen Huoxue decoction in treating intervertebral disc degeneration based on network pharmacology. 61
33752429 2021
34
Sheep as a Potential Model of Intradiscal Infection by the Bacterium Cutibacterium acnes. 61
33809558 2021
35
Effect of single and multilevel artificial inter-vertebral disc replacement in lumbar spine: A finite element study. 61
33706581 2021
36
Substrate Topography Regulates Differentiation of Annulus Fibrosus-Derived Stem Cells via CAV1-YAP-Mediated Mechanotransduction. 61
33715372 2021
37
A challenging playing field: Identifying the endogenous impediments to annulus fibrosus repair. 61
33778407 2021
38
Effect of Core Stabilizing Training on Young Individuals Presenting Different Stages of Degenerative Disc Disease-Preliminary Report. 61
33800555 2021
39
Comparison of lumbar degenerative disc disease using conventional fast spin echo T2W MRI and TT2 fast spin echo dixon sequences. 61
33684306 2021
40
Overexpression of long non-coding RNA XIST promotes IL-1β-induced degeneration of nucleus pulposus cells through targeting miR-499a-5p. 61
33722663 2021
41
For whom the disc tolls: intervertebral disc degeneration, back pain and toll-like receptors. 61
33738788 2021
42
Understanding embryonic development for cell-based therapies of intervertebral disc degeneration: Toward an effort to treat disc degeneration subphenotypes. 61
32564440 2021
43
microRNA-155-3p attenuates intervertebral disc degeneration via inhibition of KDM3A and HIF1α. 61
33486545 2021
44
MiR-874-3p plays a protective role in intervertebral disc degeneration by suppressing MMP2 and MMP3. 61
33482178 2021
45
[Experimental study on the effect of zinc finger protein A20 on lumbar intervertebral disc degeneration in rabbits]. 61
33719247 2021
46
Major ceRNA regulation and key metabolic signature analysis of intervertebral disc degeneration. 61
33676464 2021
47
Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-κB axis. 61
33242601 2021
48
Is the Distribution Pattern of Modic Changes in Vertebral End-plates Associated With the Severity of Intervertebral Disc Degeneration?: A Cross-sectional Analysis of 527 Caucasians. 61
33684588 2021
49
Intervertebral disc degeneration and regeneration: a motion segment perspective. 61
33763848 2021
50
Role of microRNA-15a-5p/Sox9/NF-κB axis in inflammatory factors and apoptosis of murine nucleus pulposus cells in intervertebral disc degeneration. 61
33781831 2021

Variations for Degenerative Disc Disease

Expression for Degenerative Disc Disease

Search GEO for disease gene expression data for Degenerative Disc Disease.

Pathways for Degenerative Disc Disease

Pathways related to Degenerative Disc Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.21 GDF5 COL9A3 BMP2 ASPN ACAN
2 10.9 SOX9 GDF5 BMP2 ACAN
3 10.89 COL9A3 ASPN ACAN

GO Terms for Degenerative Disc Disease

Biological processes related to Degenerative Disc Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.92 VDR SOX9 RELA CALCA BMP2
2 positive regulation of gene expression GO:0010628 9.85 VDR SOX9 MIR155 MIR132 HIF1A BMP2
3 skeletal system development GO:0001501 9.73 VDR SOX9 BMP2 ACAN
4 cellular response to interleukin-1 GO:0071347 9.67 SOX9 RELA HIF1A
5 epithelial to mesenchymal transition GO:0001837 9.63 SOX9 HIF1A BMP2
6 chondrocyte development GO:0002063 9.58 SOX9 ACAN
7 positive regulation of chondrocyte differentiation GO:0032332 9.58 SOX9 GDF5
8 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.58 RELA HIF1A BMP2
9 endocardial cushion morphogenesis GO:0003203 9.57 SOX9 BMP2
10 positive regulation of cartilage development GO:0061036 9.56 SOX9 BMP2
11 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.55 TRPV1 CALCA
12 negative regulation of bone mineralization GO:0030502 9.54 SOX9 HIF1A
13 negative regulation of pri-miRNA transcription by RNA polymerase II GO:1902894 9.51 SOX9 RELA
14 negative regulation of ossification GO:0030279 9.5 SOX9 HIF1A CALCA
15 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.48 RELA BMP2
16 cartilage development GO:0051216 9.46 SOX9 HIF1A GDF5 BMP2
17 response to pain GO:0048265 9.43 TRPV1 COMT CALCA
18 negative regulation of gene expression GO:0010629 9.43 VDR SOX9 MIR155 MIR132 HIF1A BMP2
19 negative regulation of mesenchymal cell apoptotic process GO:2001054 8.8 SOX9 HIF1A GDF5

Molecular functions related to Degenerative Disc Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring compression resistance GO:0030021 8.62 ASPN ACAN

Sources for Degenerative Disc Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....